The drug significantly reduces pain within two hours after the onset of migraine, in some patients – in 15 minutes.
The US Food and Drug Administration has approved Pfizer’s rapid-acting nasal spray for the treatment of migraine. The drug is called Zavzpret. It will be available in pharmacies in July 2023, writes Science Alert.
“The FDA’s approval of Zavzpret marks a significant breakthrough for people with migraine who need pain relief and prefer alternatives to oral medications,” said Pfizer’s chief commercial officer Angela Hwang in a statement.
It is noted that a phase three study of this drug proved that it alleviated pain in some migraine sufferers in as little as 15 minutes.
“As a fast-absorbing nasal spray, Zavzpret offers an alternative treatment option for people who need pain relief but cannot take oral medications because of nausea or vomiting,” New England said. Institute of Neurology and Headache in a statement.
The drug was tested by 1,405 people. Half of them took a dose of the spray, while the rest took a placebo.
Let us remind you, early scientists called sleep the cause of migraine. Headaches appeared in the participants of the experiment only one day after repeated sleep and after several hours of waking up in bed in the hope of falling asleep.
American cures migraines with a plant-based diet
news Correspondent.net on Telegram. Subscribe to our channel Athletistic
Source: korrespondent
I am Ben Stock, a passionate and experienced digital journalist working in the news industry. At the Buna Times, I write articles covering technology developments and related topics. I strive to provide reliable information that my readers can trust. My research skills are top-notch, as well as my ability to craft engaging stories on timely topics with clarity and accuracy.